Roy Buchanan

Stock Analyst at Citizens Capital Markets

(0)
# 4834
Out of 5,326 analysts
64
Total ratings
30.77%
Success rate
-25.91%
Average return
18 Stocks
Name Action Price Target Current % Upside Ratings Updated
ANTX AN2 Therapeutics
Reiterates: Market Outperform
5 5
1.31 281.68% 8 Mar 26, 2025
INO Inovio Pharmaceutica...
Reiterates: Market Outperform
18 18
1.92 837.5% 3 Mar 14, 2025
CDTX Cidara Therapeutics
Initiates Coverage On: Market Outperform
46
21.46 114.35% 1 Mar 12, 2025
CVAC CureVac
Reiterates: Market Outperform
16 16
3.27 389.3% 8 Feb 14, 2025
TPG TPG
Reiterates: Market Perform
n/a
n/a n/a 1 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
7 4
0.88 354.55% 3 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
21 21
5.66 271.02% 12 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
23 14
0.88 1490.91% 1 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
33 33
6.92 376.88% 1 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
24 7
0.86 713.95% 2 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 5 Oct 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
4 5
3.32 50.6% 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
25 27
10.89 147.93% 5 Nov 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Jul 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
443 448
599.36 -25.25% 2 Mar 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
14 16
9.12 75.44% 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Feb 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Outperform
420
2.67 15630.34% 1 Sep 14, 2021